News and Educations

Dear Healthcare Professional Letter to physicians concerning the supply shortage of medicinal products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) and consequent temporary treatment recommendations

01.07.2009

Medical Intertrade d.o.o., the marketing authorisation holder of the Genzyme medicinal products in the Republic of Croatia, in cooperation with the Agency for Medicinal Products and Medical Devices, sent a Dear Healthcare Professional Letter to prescribing physicians concerning the supply shortage of medicinal products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) and consequent temporary treatment recommendations.

more

Publication of the new Ordinance on the Conditions and Procedure for Determining Good Manufacturing Practice Requirements and the Procedure for Issuance of Manufacturing Licence and the Good Manufacturing Practice Certificate

01.07.2009

The new Ordinance on the Conditions and Procedure for Determining Good Manufacturing Practice Requirements and the Procedure for Issuance of Manufacturing Licence and the Good Manufacturing Practice Certificate was published on 29 June 2009 in the Official Gazette, No. 74/09. The Ordinance will come into effect on the eighth day from the date of the publication in the Official Gazette. The link to this Ordinance can be found in the Legislation section of the ALMP website.

more

No change on safety profile of stimulant medication used in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)

19.06.2009

The U.S. Food and Drug Administration (FDA) reported that no conclusions can be drawn regarding the change of the safety profile of this class of medicinal products from the results of the recently published study which, based on 10 cases, established an association between sudden death and the use of stimulant medications to treat children and adolescents with ADHD.

more

Safety information for medicinal products containing cefepime as active substance

18.06.2009

The U.S. Food and Drug Administration (FDA) informed about the completion of the assessment procedure for possible increased risk of higher mortality in patients using cefepime. The conclusion was that there were no data indicating increased mortality of patients treated with cefepime in comparison with those treated with other similar medicinal products. Cefepime remains an appropriate therapy for use in approved indications.

more

Recommendations of the Agency for Medicinal Products and Medical Devices on the use of Tamiflu in children under one year of age and the use of Tamiflu and Relenza in pregnant and breastfeeding women in the influenza A/H1N1 pandemic

09.06.2009

In connection with the recent outbreak of the A/H1N1 influenza, the Committee for Medicinal Products of the Agency for Medicinal Products and Medical Devices, at its 111th session, adopted the recommendations for use of antiviral medicine Tamiflu (oseltamivir) in children under one year of age, and the medicinal products Tamiflu and Relenza (zanamivir) in pregnant and breastfeeding women in the case of a declared influenza A/H1N1 pandemic (The World Health Organization has raised its pandemic alert level for the A/H1N1 influenza virus to phase 6). The recommendations are harmonised with the recommendations of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

more